Related Experiment Video

Updated: Feb 1, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Iron Deficiency in Heart Failure: An Overview

Stephan von Haehling1, Nicole Ebner1, Ruben Evertz1

  • 1Department of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany.

JACC. Heart Failure
|December 17, 2018
PubMed

Insights

Iron deficiency is common in heart failure patients, impacting quality of life. Intravenous iron, particularly ferric carboxymaltose, shows efficacy in improving symptoms and potentially reducing hospitalizations and cardiovascular mortality.

Area of Science:

  • Cardiology
  • Hematology
  • Internal Medicine

Background:

  • Iron deficiency affects up to 50% of heart failure patients.
  • It is linked to decreased exercise capacity, well-being, and quality of life.

Purpose of the Study:

  • To review the pathophysiology, prevalence, clinical impact, and treatment of iron deficiency in heart failure.
  • To highlight the efficacy of intravenous iron, specifically ferric carboxymaltose.

Main Methods:

  • Review of current literature and clinical studies on iron deficiency in heart failure.
  • Analysis of data from meta-analyses regarding treatment outcomes.

Main Results:

  • Established diagnostic criteria for iron deficiency in heart failure with reduced ejection fraction.
  • Intravenous iron, particularly ferric carboxymaltose, improves exercise capacity, quality of life, and functional class.
  • Meta-analyses suggest benefits in reducing heart failure hospitalizations and cardiovascular mortality.

Conclusions:

  • Iron deficiency is a significant comorbidity in heart failure with clear diagnostic criteria.
  • Intravenous iron therapy is preferred over oral iron for efficacy in this patient population.
  • Ferric carboxymaltose demonstrates positive effects on key clinical outcomes, with ongoing trials investigating morbidity and mortality benefits.

Keywords:
ferric carboxymaltoseheart failureiron deficiencytreatment

More Related Videos

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.4K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
920
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
882
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
336
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
966
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
312